# EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

> **NCT06556563** · PHASE3 · RECRUITING · sponsor: **NovoCure GmbH** · enrollment: 741 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DEVICE:** Optune® device
- **DRUG:** Temozolomide
- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06556563
- **Lead sponsor:** NovoCure GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-03
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 741 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556563, "EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06556563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*